Literature DB >> 32202140

Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities.

Feifei Yang1,2, Lina Han1, Na Zhao1, Yang Yang2, Di Ge1, Hua Zhang1, Yihua Chen2.   

Abstract

Aim:   Histone deacetylases (HDACs) are one of the validated targets for cancer treatments. In our previous work, we designed a series of bis-substituted aromatic amide HDAC inhibitors (HDACis), among which compounds 7 and 8 showed promising anticancer effects. However, the low solubilities prevented their subsequent developments. We developed additional thiophene-based hydroxamate HDACis in order to improve their physicochemical properties. Materials & methods: In vitro biological evaluations of these analogs revealed potent antiproliferative and antimigrated activities. More importantly, compound 10h exhibited excellent in vivo antitumor activities in MDA-MB-231 xenograft model mice. Furthermore, 10h showed better anticancer activities and drug-like properties than 7. Results & conclusion: Our results proved that thiophene-based hydroxamate HDACis can serve as a promising framework for developing potential anticancer agents.

Entities:  

Keywords:  antimetastatic; antiproliferative; bis-substituted aromatic amide; histone deacetylase inhibitors; structure–activity relationship

Mesh:

Substances:

Year:  2020        PMID: 32202140     DOI: 10.4155/fmc-2019-0343

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  2 in total

Review 1.  HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer.

Authors:  Cristina Maccallini; Alessandra Ammazzalorso; Barbara De Filippis; Marialuigia Fantacuzzi; Letizia Giampietro; Rosa Amoroso
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-26

2.  Antimicrobial efficacy of Egyptian Eremina desertorum and Helix aspersa snail mucus with a novel approach to their anti-inflammatory and wound healing potencies.

Authors:  Nessma A El-Zawawy; Mahy M Mona
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.